“[The] really key thing about this deal is not the value it creates for consumer, but how it unlocks bigger cash flows near term to invest in pharma near term,” says Chief Executive Emma Walmsley.
Glaxo And Pfizer Raise The Question: Should Drug Companies Sell Toothpaste and Chapstick?
